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Abstract-This meta-analysis aimed to compare the diagnostic performance of 
contrast-enhanced ultrasound (CEUS), conventional ultrasound (US) combined with 
CEUS (US+CEUS), and US for distinguishing breast lesions. From thorough 
literature research, studies that compared the diagnostic performance of CEUS vs. US 
or US+CEUS vs. US, using pathology results as the gold standard, were included. A 
total of 10 studies were included, of which 9 compared the diagnostic performance of 
CEUS and US, and 5 studies compared US+CEUS and US. In those comparing CEUS 
vs. US, the pooled sensitivity was 0.93 (95%CI: 0.91-0.95) vs. 0.87 (95%CI: 0.85-
0.90), and pooled specificity was 0.86 (95%CI: 0.84-0.88) vs. 0.72 (95%CI: 0.69-
0.75). In studies comparing US+CEUS vs. US, the pooled sensitivity was 0.94 
(95%CI: 0.92-0.96) vs. 0.87 (95%CI: 0.84-0.90), and pooled specificity was 0.86 
(95%CI: 0.82-0.89) vs. 0.80 (95%CI: 0.76-0.84). In terms of diagnosing breast 
malignancy, areas under the SROC curve (AUC) of both CEUS (P=0.003) and 
US+CEUS (P=0.000) were statistically higher than that of US. Both CEUS alone and 
US+CEUS had better diagnostic performance than US in differentiation of breast 
lesions, and US+CEUS also had low negative likelihood ratio. 
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Introduction 
Globally, breast cancer is the most common cancer and the leading cause of 
cancer death among women (Torre et al. 2015). High-frequency ultrasonography has 
become the first-line imaging modality in evaluation of breast lesions due to its 
widespread availability, non-invasiveness, and low expense. However, conventional 
ultrasound (US) faces some limitations in differentiating benignity from malignancy 
because of overlapping sonographic findings in some cases (Zhi et al. 2007). Unlike 
conventional US, the newly emerging contrast-enhanced ultrasound (CEUS) helps 
evaluate blood distribution and perfusion of tumors, thus offering more valuable 
information for lesion differentiation (Harvey et al. 2015; Ishii et al. 2017; Lekht et al. 
2016). 
However, the capability of CEUS to accurately diagnose breast cancer remains 
unclear. A meta-analysis of 16 studies found that the pooled sensitivity and specificity 
of CEUS alone in diagnosing breast cancers were 0.86 and 0.79 (Hu et al. 2014), 
which were similar to the sensitivity (0.82-0.95) and specificity (0.71-0.79) of 
conventional US reported in several studies (Du et al. 2012; Liu et al. 2008; Xiao et 
al. 2016). This difference was ascribed to CEUS’ capability to delineate the 
morphological features of breast masses, which conventional US does not possess. 
Therefore, in order to make full use of the sonographic information offered by each 
technique, conventional US and CEUS (US+CEUS) were combined. While several 
studies found improved sensitivity (US+CEUS: 0.88-0.97 vs. US: 0.82-0.89) and 
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specificity (US+CEUS: 0.82-0.93 vs. US: 0.78-0.79) (Du et al. 2012; Wang et al. 
2011; Xiao et al. 2016), no improvement was found in other studies (Fujimitsu et al. 
2016; Sorelli et al. 2010).  
Until now, no meta-analysis has compared the diagnostic performance of CEUS 
and US or US+CEUS and US in differentiating breast cancers. Here we systematically 
reviewed the literature via a meta-analysis to compare the diagnostic performance of 
these ultrasound techniques on benign and malignant breast lesions, using pathological 
results as the reference standard. 
Methods 
Our meta-analysis was conducted in accordance with the “Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses” (PRISMA) (Moher 2009). We 
included studies of patients suspected of having one breast mass or more, using US and 
CEUS, or US and US+CEUS as diagnostic methods, histopathological or cytological 
results for comparison, and reporting true positive (TP), false positive (FP), true 
negative (TN), and false negative (FN), and the study type was diagnostic test.   
Search Strategy 
       We searched online all published studies without language restrictions from the 
earliest available date of indexing to August 31, 2016 in PubMed, EMBASE, and 
Cochrane Library databases. We also searched the most comprehensive Chinese 
academic databases in medicine: China National Knowledge Infrastructure, Chinese 
Biomedical Literature Database, and Wanfang Database. The references of retrieved 
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articles were also hand-searched. The search strategy included the following terms: 
(“contrast enhanced ultrasound” OR “contrast enhanced ultrasonography” OR “CEUS”) 
in combination with (“breast”) and (“ultrasound” OR “ultrasonography” OR 
“sonography”). The search strategy for Chinese papers was similar to that used for 
English papers (S1 File). 
Study Selection 
All published studies that compared the diagnostic accuracy of CEUS, US+CEUS, 
and US for breast lesions were identified. Study selection was performed independently 
by two researchers. If disagreements occurred, a third reviewer made the adjudication. 
First, the titles and abstracts were screened to determine the potential usefulness of the 
articles, followed by full-text screening according to the following criteria (1) patients: 
suspect of having breast mass,  (2) studies did obtain informed consent from each study 
participant, and each study was approved by an ethics committee or institutional review 
board, (3) index tests: both US and CEUS, or both US and US+CEUS were used for 
diagnostic purposes, (4) studies compared the performance of CEUS and US or 
US+CEUS and US for differentiating benign from malignant breast masses, (5) studies 
of harmonic-mode CEUS, (6) reference standard was either histopathology or cytology, 
and (7) TP results and FN results or TN results and FP results were available or could 
be derived adequately. Exclusion criteria were (1) case reports or case series, review 
articles, letters, comments, (2) studies of contrast-enhanced power or color Doppler 
sonography, (3) duplicate publications in different databases and studies using the same 
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study population from the same institution, (4) fewer than 15 cases confirmed by 
reference standard, and (5) postsurgical studies.  
Data Extraction 
Two authors independently extracted the data from eligible studies, and 
discrepancies were resolved by discussion. Adjudication by a third investigator was 
performed when disagreements occurred. Extracted information included (1) first 
author name, (2) year of publication, (3) age, (4) number of patients, (5) number of 
masses, (6) total number of malignant masses, (7) mass long axis, and (8) reference 
standard. The diagnostic accuracy data on each index test and number of TP, TN, FP, 
and FN findings for each index test were recorded or calculated. Sensitivity, specificity, 
positive likelihood ratio (LR+), and negative likelihood ratio (LR-) were extracted or 
calculated as follows: sensitivity=TP/(TP+FN), specificity= TN/(TN+FP), LR+= 
sensitivity/(1- specificity), and LR-=(1- sensitivity)/ specificity. If more than one CEUS 
criterion was used in one individual literature, the data of the one with the highest 
Youden index or area under the curve were extracted or calculated. 
To ensure the consistency of subjects and methods in the included studies, we 
extracted, pooled, and compared the diagnostic accuracy of US and CEUS from the 
literature that compared these two techniques (Group 1), and studies comparing US and 
US+CEUS were classified into another group (Group 2). 
Quality Assessment 
All included studies were assessed for methodological quality by two authors 
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independently using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy 
Studies) tool (Whiting 2011). If the two readers disagreed, a third reader adjudicated. 
None of the readers was involved in any of the included studies. The QUADAS-2 
checklist consists of four domains: patient selection, index test, reference standard, and 
flow/timing. Based on several questions, each of the four domains was assessed for risk 
of bias, but only the first three domains were assessed for applicability concerns.  
Statistical Analysis 
Sensitivity, specificity, LR+, and LR- were extracted or calculated from individual 
studies and then pooled to assess diagnostic accuracy. Summary receiver operating 
characteristic (SROC) curves were constructed, also to examine diagnostic accuracy. 
Between-study heterogeneity was tested using inconsistency index (I2) statistics, and I2 
values greater than 50% were considered to indicate substantial heterogeneity (Higgins 
2003). A random-effects model was applied in the analysis for the heterogenic data, 
and the fixed-effects model was used otherwise (DerSimonian and Laird 1986).  
Likelihood ratio (LR) can be interpreted as follows: a LR of 0 excludes disease, a 
LR of infinity (∞) excludes normality, and a LR of 1 means no change in likelihood of 
disease. For the diagnostic information to have high probability of altering clinical 
management, a LR greater than 10 or less than 0.1 would be required for a positive or 
negative test result, respectively. Moderate informational value can be achieved with 
LRs of 5-10 and 0.1-0.2, and LRs of 2.0-5.0 and 0.2-0.5 indicate very little 
informational value (Sadigh et al. 2012). 
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A Deek’s funnel plot was used to assess the publication bias of all included studies. 
Z-test was used to test differences of area under SROC curve (AUC) between CEUS 
and US, or between CEUS+US and US. 
A sensitivity analysis was performed to investigate the influence of the publication 
language on the diagnostic performance of different ultrasound techniques.  
In CEUS studies, Subgroup analysis was performed on the dosage of SonVue, 
which was used as the contrast in 8 of these 9 studies. Meanwhile, Subgroup analysis 
was performed on diagnostic criteria for malignancy in US studies.  
The meta-analysis was performed using Meta Disc version 1.4 (Meta-DiSc, 
Javier.zamora), and Stata 14 was used to analyze publication bias. MedCalc Statistical 
Software version 13.0.2 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org) was used to compare SROCs. All statistical tests were two-
sided, and statistical significance was defined as P<0.05. 
Results 
Search Results and Selected Articles 
A total of 1359 articles were identified from the database. After primary title and 
abstract screening, 54 studies were identified for further full-text evaluation, finally 
leaving 10 qualified studies in this meta-analysis (Fig. 1).  
The 10 included studies were classified into two groups according to the ultrasound 
techniques evaluated in each study. Of the 9 studies in Group 1 that compared the 
diagnostic accuracy of CEUS vs. US, 7 were conducted in China and the other 2 in Italy 
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and Japan, respectively. Of the 5 studies in Group 2 that compared the diagnostic 
accuracy of US+CEUS vs. US, all were conducted in China. The diagnostic accuracy 
of CEUS vs. US and US+CEUS vs. US were both compared in 4 studies. 
In Group 1, with the exception of one male, all patients were female (Ricci et al. 
2007) (age range 19-88 years), including 1545 patients and 1609 breast masses, of 
which 751 masses (751/1609, 46.7%) were malignant. In Group 2, all patients were 
female (age range 19-88), including 924 patients and 959 breast masses, of which 505 
masses (505/959, 52.6%) were malignant.  
Quality Assessment 
The characteristics of all 10 studies are shown in Table 1.  The methodological 
quality of the included papers was assessed using the QUADAS-2 tool (Fig. 2). In the 
Group 1 studies (CEUS vs. US), one study was scored high risk because the threshold 
for malignancy of US and CEUS was not pre-specified (An et al. 2014), while 2 studies 
were scored  as having unclear risk because it was not clear whether the US threshold 
was pre-specified (Miyamoto et al. 2014; Ricci et al. 2007). In Group 2 studies 
(US+CEUS vs. US), one study (An et al. 2014) was scored high risk and another study 
(Le et al. 2012) unclear risk, for the above reasons. 
Analyses of studies in Group 1 (CEUS vs. US) 
Diagnostic Accuracy of CEUS for Malignant Breast Lesions  
To diagnose malignant breast lesions, the sensitivity and specificity of CEUS in 
individual studies ranged from 0.76-1.00 and 0.82-0.97 (respectively), and the pooled 
  10 
sensitivity and specificity of CEUS were 0.93 (95% CI: 0.91-0.95) and 0.86 (95% CI: 
0.84-0.88). The included studies were statistically heterogeneous in the estimate of 
sensitivity (I2=61.2%) but not in the estimate of specificity (I2= 22.4%) (Fig. 3). The 
pooled LR+ and LR- were 6.48 (95%CI: 5.55-.57) and 0.10 (95%CI: 0.06-0.16), 
respectively. 
Diagnostic Accuracy of US for Malignant Breast Lesions  
In the 9 studies that compared the performance of CEUS and US to diagnose 
malignant breast lesions, the sensitivity and specificity of the US in individual studies 
ranged from 0.69-0.95 and 0.58-0.92 (respectively), and the pooled sensitivity and 
specificity of US were 0.87 (95% CI: 0.85-0.90) and 0.72 (95% CI: 0.69-0.75). The 
included studies were statistically heterogeneous in the estimate of sensitivity 
(I2=78.6%) and specificity (I2=84.6%) (Fig. 3). The pooled LR+ and LR- were 3.50 
(95%CI: 3.59-4.73) and 0.20 (95%CI: 0.13-0.31), respectively. 
Publication Bias 
The Deek’s funnel plot asymmetry test showed no publication bias among CEUS 
(P=0.74) and US (P=0.56) studies.  
Comparison of the Accuracy of CEUS and US for Detection of 
Malignant Breast Lesions  
The area under the SROC curve (AUC) of CEUS (AUC=0.954, SE=0.008) of the 
9 studies that compared the diagnostic performance of CEUS and US was significantly 
higher than that of US (AUC=0.884, SE=0.022) (Z=3.012, P=0.003) (Fig. 4). 
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Subgroup Analysis 
In subgroup analysis of CEUS studies (Table 2), the heterogeneity of sensitivity 
decreased in the group with dosage ≤ 2.4 ml but increased in the group with dosage > 
2.4 ml, and the heterogeneity of specificity increased in both groups. Meanwhile, there 
was no significant difference in sensitivity or specificity between these two subgroups 
(P=0.368). Subgroup analysis was not performed on paper quality (assessed by 
QUADAS-2) or study design, due to limited sample size in subgroups. 
In subgroup analysis of US studies (Table 2), heterogeneity was still observed in 
sensitivity and specificity even when lesions were stratified by diagnostic criteria for 
malignancy, and there was no significant difference in sensitivity or specificity between 
studies using BIRADS≥4b as diagnostic criteria and studies that did not use it (P=0.147). 
Also, subgroup analysis was not performed on paper quality (assessed by QUADAS-2) 
or study design, due to limited sample size in subgroups. 
Sensitivity Analysis 
A sensitivity analysis was performed to investigate the influence of the publication 
language on the diagnostic performance of different ultrasound techniques. After 
excluding the studies published in Chinese, the sensitivity and specificity of CEUS in 
studies published in English were 0.93 (95%CI:0.91-0.95) and 0.88 (95%CI: 0.85-0.91), 
and the sensitivity and specificity of US were 0.87 (95%CI: 0.83-0.90) and 0.72 (95%CI: 
0.69-0.74), both of which were similar to figures in overall studies, i.e., CEUS: 0.93 
(95%CI: 0.91-0.95) and 0.86 (95%CI: 0.84-0.88), US: 0.87 (95%CI: 0.85-0.90) and 
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0.72 (95%CI: 0.69-0.75). 
Analyses of Studies in Group 2 (US+CEUS vs. US) 
Diagnostic Accuracy of US+CEUS for Malignant Breast Lesions  
The sensitivity and specificity of US+CEUS to diagnose malignant breast lesions 
in individual studies ranged from 0.85-0.98 and 0.82-0.90, respectively. The pooled 
sensitivity and specificity of US+CEUS were 0.94 (95%CI: 0.92-0.96) and 0.86 
(95%CI: 0.82-0.89), respectively. The included studies were statistically heterogeneous 
in their estimate of sensitivity (I2=80.5%) but not of specificity (I2=40.0%) (Fig. 5). 
The pooled LR+ and LR- were 6.43 (95%CI: 5.14-8.04) and 0.07 (95%CI: 0.03-0.18), 
respectively. 
Diagnostic Accuracy of US for Malignant Breast Lesions  
In the 5 studies in Group 2, the sensitivity and specificity of US to diagnose 
malignant breast lesions in individual studies ranged from 0.78-0.95 and 0.75-0.88, 
respectively. The pooled sensitivity and specificity of US were 0.87 (95%CI: 0.84-0.90) 
and 0.80 (95%CI: 0.76-0.84), respectively. The included studies were statistically 
heterogeneous in the estimate of sensitivity (I2= 64.0%) but not of specificity (I2= 
41.1%) (Fig. 5). The pooled LR+ and LR- were 4.39 (95%CI: 3.63-5.29) and 
0.17(95%CI: 0.11-0.25), respectively.  
Publication Bias 
The Deek’s funnel plot asymmetry test showed no publication bias among studies 
for US+CEUS (P=0.82) and US (P=0.62).  
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Comparison of the accuracy of US and US+CEUS for malignant 
breast lesions 
The AUC of SROC of US+CEUS (AUC=0.965, SE=0.009) was significantly 
higher than that of US (Group 2) (AUC=0.911, SE=0.011) (Z=3.826, P=0.000) (Fig. 
6). 
Sensitivity Analysis 
After excluding studies published in Chinese, the sensitivity and specificity of 
US+CEUS in studies published in English were 0.96 (95%CI: 0.94-0.98) and 0.84 
(95%CI: 0.80-0.88), and the sensitivity and specificity of US were 0.89 (95%CI: 0.85-
0.92) and 0.77 (95%CI: 0.72-0.82), both of which were similar to findings in overall 
studies (US+CEUS: 0.94 (95%CI: 0.92-0.96) and 0.86 (95%CI: 0.82-0.89), US: 0.87 
(95%CI: 0.84-0.90) and 0.80 (95%CI: 0.76-0.84)).  
Discussion 
Our meta-analysis compared the diagnostic performance of CEUS, US, and 
US+CEUS for differentiating benign from malignant breast lesions, using pathology as 
the reference standard. However, the diagnostic accuracy of these ultrasound 
techniques varies among different studies due to variation in examiners, types of CEUS 
contrast, analyzing software, etc. (Du et al. 2012; Hu et al. 2014; Ma et al. 2015; Ricci 
et al. 2007). To minimize data heterogeneity due to the study population, we re-
classified the studies into two groups in this meta-analysis: Group 1, which compared 
the diagnostic accuracy of CEUS vs. US; and Group 2, which compared US+CEUS vs. 
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US, in order to compare the diagnostic performance in the same study population of 
each group (Alrajab et al. 2013; Schwab et al. 2016). 
The acquisition modes during CEUS scanning, including power Doppler, color 
Doppler, and harmonic modes, might also have introduced variation among studies. In 
this study, we included only studies of CEUS that were performed with the harmonic 
mode, for the following considerations. Compared to power or color Doppler mode, the 
harmonic mode has fewer limitations in the frame rate and motion artifacts (Ma et al. 
2016).   And additionally, harmonic mode detects signals using a low mechanical index, 
which causes minimal bubble destruction and allows continuous real-time assessment 
of the microvascularization (Cosgrove and Blomley 2004). 
Our data showed that most of the included papers published in English were 
actually performed in China (6/8, 75%), which was similar to the findings of two other 
meta-analyses assessing the diagnostic performance of CEUS on breast lesions, with 
10/15 (Ma et al. 2016)  and 4/6 (Hu et al. 2014) performed in China, respectively. The 
abundance of Chinese studies in this area may be ascribed to the early approval of 
SonVue in the Chinese market and the popularity of ultrasound exams in Chinese 
clinical practice (Xu and Lu 2010). In addition, we performed searches in Chinese 
databases, which added one study to Group 1 and two studies to Group 2. As our 
sensitivity analysis showed no change in diagnostic performance when studies 
published in Chinese were excluded, all the studies published in Chinese were also 
included for final analysis. 
  15 
      As the first-line breast-imaging procedure, conventional US has shown high 
accuracy in distinguishing between benign and malignant breast lesions (Costantini et 
al. 2006), which is based on its capability to evaluate lesion features including 
morphology, echotexture, and vascular distribution. Using conventional high-
frequency US, morphological and echotexture features of malignant breast lesions have 
been fully studied, including lesion shape, orientation, margins, boundary, echo pattern, 
and posterior acoustic features (Costantini et al. 2006). In addition, some ultrasound 
technologies such as color and power Doppler imaging have been widely used to 
evaluate blood distribution in lesions. It has been demonstrated that angiogenesis plays 
an important role in the development of breast cancer in terms of tumor growth and 
metastasis (Drudi et al. 2012), including most of the advanced breast cancers, and some 
others at early stages, such as atypical hyperplasia or lobular carcinoma in situ (Drudi 
et al. 2012). Researchers have found that internal and surrounding vascularity on 
ultrasound are characteristic of malignancy (Ferrara et al. 2016; Sehgal et al. 2000), and 
vascular density is associated with tumor aggressiveness (Balleyguier et al. 2009).  
Together these sonographic features of conventional US offer relatively high accuracy 
in distinguishing between benign and malignant breast lesions. 
However, the evaluation of vascular distribution in tumors using power and color 
Doppler are not acceptable due to their low sensitivity in detecting the small vessels 
and slow blood flow associated with tumor neovascularity (Ferrara et al. 2016; Sehgal 
et al. 2000). Fortunately, ultrasound contrast agents are microbubbles 1-10 microns in 
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size (equal to or smaller than red blood cells), enabling the visualization of both the 
macrovasculature and microvasculature associated with tumors. Our results showed 
that CEUS alone had better diagnostic performance than US alone (AUC: 0.954 vs. 
0.884), which suggested that CEUS was helpful in differentiating malignant from 
benign breast lesions. Similarly, it has been reported that, compared to color Doppler 
in conventional US (sensitivity 83.8-95.3%, specificity 57.7-77.7%), CEUS alone has 
superior diagnostic performance in differentiating between benign and malignant breast 
lesions (sensitivity 91.4-95.5%, specificity 81.6-88.3%) (Liu et al. 2008; Miyamoto et 
al. 2014; Xiao et al. 2016). 
It should be noted that the diagnostic performance of CEUS alone may be 
overestimated, because clinically, a 2D ultrasound screening is usually performed 
before CEUS, and the 2D sonographic information may inadvertently affect the 
evaluation of the diagnostic performance of CEUS alone. 
In addition to the advantages of CEUS compared to conventional US, CEUS 
examination alone has several limitations, including the inability to delineate the 
morphological characteristics of lesions and the variation in vascular distribution 
patterns in tumors with different histopathologic types  (Wang et al. 2011). For example, 
invasive ductal carcinoma, which accounts for the majority of breast malignancies, 
showed heterogeneous enhancement on CEUS. Conversely, most medullary 
carcinomas showed homogenous enhancement (Wang et al. 2011). However, because 
invasive ductal carcinomas have irregular shape and poorly defined margins, while 
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medullary carcinomas have regular shapes and well-defined margins, CEUS alone 
would not be a sufficiently sensitive tool with which to differentiate special types of 
cancers. Therefore it is reasonable to combine US with CEUS, which makes full use of 
the advantages of both techniques. Our pooled data showed that the sensitivity and 
specificity of CEUS+US were 0.94 (95% CI: 0.92-0.96) and 0.86 (95% CI: 0.82-0.89), 
respectively, and the AUC of SROC of CEUS+US was higher than that of US (0.965 
vs. 0.911), which is consistent with the findings of several other researchers, 
underlining the advantages of CEUS+US over US alone (Du et al. 2012; Liu et al. 2008; 
Xiao et al. 2016). 
Generally, a helpful diagnostic test should have a high positive LR (>5: good at 
ruling in a disease) and low negative LR (<0.2: good at ruling out a disease) (Cronin et 
al. 2008). Compared to US, CEUS and US+CEUS are better at confirming malignancy 
due to the positive LR+, and are also helpful in ruling out malignancy due to lower LR-. 
Additionally, as US+CEUS with LR-<0.1 is highly capable of excluding all malignancy, 
a negative US+CEUS usually indicates that no further diagnostic tests are required. 
Heterogeneity 
In Group 1, heterogeneity was found in the sensitivity and specificity of US, and 
in the sensitivity of CEUS, which persisted even after subgroup analysis. In Group 2, 
heterogeneity was found in the sensitivity of both US and US+CEUS, but subgroup 
analysis was not conducted because of the limited number of studies included. 
For US, our results showed that neither use of BIRADS≥4b as the diagnostic 
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criterion for malignancy, paper quality assessed by QUADAS-2, nor 
prospective/retrospective study design were sources of heterogeneity. Heterogeneity 
may have arisen from the inclusion criteria, ultrasound devices, and probe frequencies. 
The variations among studies in the stage of included lesions may introduce differences 
in malignant frequency in study populations, affecting the diagnostic performance of 
an ultrasound technique (Du et al. 2012; Liu et al. 2008; Xiao et al. 2014; Xiao et al. 
2016; Zhang et al. 2014). In the studies comprising this meta-analysis, a total of 8 
ultrasound systems (Esatune (Ricci et al. 2007), Esaote (Zhao et al. 2010), HDI 5000 
(Liu et al. 2008), Philips IU22 (An et al. 2014; Liu et al. 2008; Xiao et al. 2014), 
AplioXG (Miyamoto et al. 2014), Prosound α10 (Miyamoto et al. 2014), LOGIQ E9 
and LOGIQ 9 (Zhang et al. 2014) were used, with the probe frequencies ranging from 
5MHz to 15MHz, either of which might cause the heterogeneity among studies. 
        As to CEUS, our studies showed that neither the dosage of SonVue, paper quality 
assessed by QUADAS-2, nor prospective/retrospective design were sources of 
heterogeneity. Potential heterogeneity sources may include differences in contrast 
techniques, software for CEUS imaging processing, or criteria for diagnosing 
malignancy. Here to, different manufactures use different contrast techniques, such as 
Contrast-Tuned Imaging (CnTI) of Esaote (Du et al. 2012; Le et al. 2012; Ricci et al. 
2007; Zhao et al. 2010), Coded Angio Harmonic (CAH) of GE (Miyamoto et al. 2014; 
Zhang et al. 2014), and Pulse Inversion Harmonic Imaging (PIHI) of Philps (An et al. 
2014; Liu et al. 2008; Xiao et al. 2014; Xiao et al. 2016), etc. Furthermore, different 
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quantitative analysis software was used in some studies, such as Q-lab (An et al. 2014; 
Liu et al. 2008) and Qontrast (Du et al. 2012; Le et al. 2012; Ricci et al. 2007; Zhao et 
al. 2010). The most common criteria for diagnosing malignancy in CEUS examinations 
were (1) peripheral enhancement, based on more peripheral micro-vessel distribution 
in the tumor’s angiogenesis, and (2) the characteristic enhancement pattern with early, 
intense wash-in and fast wash-out phases, associated with a tumor’s arteriovenous 
shunts (Drudi et al. 2012). In addition, other criteria for malignancy were used in some 
studies, such as strengthening of enhancement (Zhang et al. 2014), scoring system (Du 
et al. 2012; Xiao et al. 2014), and inhomogeneous enhancement (An et al. 2014) 
Limitations 
There were several limitations to our study. First, only 10 eligible studies were 
included in two groups (9 and 5 in Group 1 and 2, respectively and 4 in both), and this 
small sample may limit the power of the data analysis or the generalizability of the 
study findings. Second, most eligible studies were conducted in Asia (8 of 9 CEUS vs. 
US studies and 5 of 5 US+CEUS vs. US studies), and this uneven geographical 
distribution may cause variations because of the health-care gap between regions. Also, 
the differences in cancer pathology between ethnic groups may be another source of 
variation. Third, there is a limitation in our analysis. The diagnostic performances of 
CEUS and US+CEUS were not compared due to the limited number of studies included, 
and in addition, no subgroup analysis was conducted in US+CEUS vs. US studies, due 
to the limited numbers of studies in subgroups. Finally, study quality assessment 
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showed one study in Group 1 (1/9) and another in group 2 (1/5) had high risk, because 
the threshold for malignancy of US and CEUS was not pre-specified, but they had 
limited impact on the meta-analysis result due to the number.  
Conclusions 
Our meta-analysis shows that both CEUS alone and US+CEUS have better AUC 
of SROC than conventional US for distinguishing between benign and malignant breast 
lesions, and both have excellent sensitivity. Meanwhile, US+CEUS has a low negative 
likelihood ratio, which recommends its use for ruling out breast malignancy. However, 
our meta-analysis is based on a small number of studies, many of which were performed 
in a single geographic region. Further studies are therefore needed before generalization 
of this conclusion. 
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Table 1. Characteristics of included studies 
Group 1: studies compared CEUS vs. US 
Group 2: studies compared US+CEUS vs. US 
Pro: prospective design 
Retro: retrospective design 
ND: not determined  
Histo: histopathology 
Cyto: cytopathology 
Table 2. Subgroup analysis for the diagnostic performance of CEUS and US to differentiate benign 
and malignant breast lesions in studies in Group 1. 
Study  Group Year Country 
Study 
design 
No. of 
patients 
Patient age, 
min-max 
(mean), years 
No. of 
masses 
Malignant, 
no. (% of all 
masses) 
Mass long axis, 
min-max(mean), 
mm  
Reference 
standard 
Ricci et al. (2007) 1 2007 Italy Pro 48 40-81(58) 50 26(52.0) ND Histo 
Liu et al. (2008) 1&2 2008 China Pro 103 19-86(44) 103 43(41.7) 5-76 Histo 
Zhao et al. (2010) 1 2010 China Pro 71 30-78(/) 76 45(63.4) ND Histo 
Le et al. ( 2012) 2 2012 China Retro 197 13-81(48) 198 97(49.2) ND Histo 
Du et al. ( 2012) 1&2 2012 China Pro 61 27-71(48) 61 33(54.1) 8-27 Histo 
An et al. ( 2014) 1&2 2014 China Retro 73 19-68(44) 73 41(56.2) ND Histo 
Xiao et al 1. (2014) 1 2014 China Pro 475 16-84(43) 498 207(54.6) 3-49 Histo 
Miyamoto et al. 
( 2014) 
1 2014 Japan Pro 117 22-79(46) 117 35(29.9) 4-34 Histo/cyto 
Zhang et al. (2014) 1 2014 China Pro 107 31-71(ND) 107 30(28.0) 3-10 Histo 
Xiao et al 2. ( 2016) 1&2 2016 China Pro 490 21-88(46) 524 291(55.5) 2.8-56 Histo 
Ultrasound 
techniques 
Parameter Studies, 
n 
Sensitivity 
(95%CI) 
I2, % Specificity 
(95%CI) 
I2, % P for 
interaction 
CEUS Overall 9 0.93 (0.91-0.95) 61.2 0.86 (0.84-0.88) 22.4  
Dosage of SonVue*       
≤2.4 ml 3 0.91 (0.84-0.95) 5.6 0.89 (0.83-0.93) 40.6 0.368 
>2.4 ml 5 0.94 (0.91-0.95) 76.3 0.85 (0.82-0.88) 28.5 
QUADAS       
Low risk 8 0.93 (0.91-0.95) 65.4 0.86 (0.84-0.88) 31.7 / 
Unclear risk 0 / / / / 
High risk 1 / / / / 
Study design       
Pro 8 0.93 (0.91-0.95) 65.4 0.88 (0.85-0.91) 31.7 / 
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*One study using Sonazoid  (Miyamoto et al. 2014) as the contrast was excluded from the subgroup 
analysis stratified by dosage of SonVue  
# “Other” subgroup includes one study regarding BIRADS > 3 as malignancy, and five studies, in 
which BIRADS was not used as the diagnostic criteria 
I2: inconsistency index  
CEUS: contrast-enhanced ultrasound 
US: conventional ultrasound  
QUADAS: Quality Assessment of Diagnostic Accuracy Studies 
Pro: prospective design 
Retro: retrospective design 
BIRADS: Breast Imaging Reporting Data System  
  
Retro 1 / / / / 
US Overall 9 0.87 (0.85-0.90) 78.6 0.72 (0.69-0.75) 84.6  
Diagnostic Criteria 
for malignancy 
      
   BIRADS≥4b  3 0.90 (0.87-0.92) 86.0 0.76 (0.73-0.80) 88.8 0.147 
   Others# 6 0.83 (0.78-0.87) 66.4 0.66 (0.61-0.70) 75.5 
QUADAS       
  Low risk 6 0.89 (0.86-0.91) 82.8 0.77 (0.73-0.80) 72.8 / 
  Unclear risk  2 / / / / 
  High risk 1 / / / / 
Study design       
  Pro 8 0.87 (0.83-0.90) 81.1 0.72 (0.69-0.74) 85.8 / 
  Retro 1 / / / / 
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Figures 
Fig. 1. Selection process for studies included in the meta-analysis 
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Fig. 2. Risk of bias and applicability concerns graph. Summary of the 
methodological quality assessment of bias risk and applicability concerns presented 
for each domain, in percentages across all included studies in the Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS) -2 criteria. US= ultrasound, 
CEUS=contrast-enhanced ultrasound.  
Fig. 3. Forest plot of sensitivity and specificity of CEUS and US to differentiate 
benign from malignant breast lesions in studies of Group 1 (CEUS vs. US 
studies). CEUS=contrast-enhanced ultrasound, US= ultrasound.  
Fig. 4. SROC of CEUS and US to differentiate benign from malignant breast 
lesions in studies in Group 1 (CEUS vs. US).  CEUS=contrast-enhanced ultrasound, 
US= ultrasound, SROC= summary receiver operating characteristic, AUC=area under 
the curve, SE=standard error, Q*=Q index.   
Fig. 5. Forest plot of sensitivity and specificity of CEUS and US to differentiate 
benign from malignant breast lesions in studies in Group 2 (US+CEUS vs. US 
studies). US+CEUS=ultrasound combined with contrast-enhanced ultrasound, 
US=ultrasound.  
Fig. 6. SROC of US+CEUS and US to differentiate benign from malignant breast 
lesions in studies of Group 2 (US+CEUS vs. US studies). US+CEUS=ultrasound 
combined with contrast-enhanced ultrasound, US=ultrasound, SROC= summary 
receiver operating characteristic, AUC=area under the curve, SE=standard error, 
Q*=Q index.   






